1. General Conditions
1.1 Application Forms
A letter of intent must first be submitted to the Canadian Hemophilia Society before completing an application form. This is the first step of the application process. Only candidates selected by the CHS will be invited to send an application form.
Application forms may be obtained by clicking on the following link: Application Form
Applications forms must be completed and submitted electronically to the Canadian Hemophilia Society (firstname.lastname@example.org
) and one (1) original paper copy, including signatures, must be sent to the National Office of the Canadian Hemophilia Society:
666 Sherbrooke Street West, Suite 301
Montreal, QC H3A 1E7
1.2 Application DeadlineA letter of intent should be submitted to the Canadian Hemophilia Society by November 15, 2016
. This should be a brief one to two-page letter identifying the applying researcher and organization and providing a summary description of the intended area of research.
Multidisciplinary applications are welcomed. Please note that if a multidisciplinary project is sought, you are encouraged to indicate in the letter of intent and in the application how the project would proceed if only one project were to be awarded.
The CHS Peer Review Committee will invite a limited number of candidates to submit a more detailed proposal by January 9, 2017 in order to make a final selection. Grants will be offered for a one-year period to begin in April 2017.
If the CHS receives the application after the deadline date but it is postmarked on or before the deadline date, then it is considered to have been submitted on time. The names of the successful applicants will be announced in March, 2017.
First time applicants are encouraged to seek advice from experienced investigators in the preparation of their applications.
Please note that the Research Proposal (Item 13 of the application) must not exceed 2,500 words or 5 pages, excluding figures and references.
Supporting materials should include only previously published articles or materials accepted for publication.
1.3 Grant Year and Amount
Support for the Grant in the maximum amount of $20,000 is normally made for a one-year period starting on April 1. Awards must be initiated by December 31 of the year awarded. The primary intent of this program is to offer one or two $20,000 research grants, to a maximum of $40,000 for one year.
Depending upon the number and quality of applications, funding for different amounts is possible, as is the offering of more than one grant, within however, the allotted total budget stated above.
The major portion of each grant would be to cover the research time for the successful candidate(s) and research assistants. A small amount can be devoted to project expenses.1.4 Payments
Award payments are normally made twice a year to the financial officer of the host institution. 1.5 Research Summaries
The Canadian Hemophilia Society (CHS) requires, within the application form, a 200-word typewritten lay description of the research to be undertaken (in non-scientific, Grade 12 readability) for inclusion in the Society's publications should the proposal be accepted.
1.6 Notification of Grants
Following funding decisions, successful applicants will be sent official notification informing them of the type, duration and amount of their grant. A copy of the notification is sent to the accountant at the institution concerned. The award must be acknowledged by returning an acceptance note within 15 days of the CHS notification otherwise the award will be withdrawn. Unsuccessful applicants are also advised at the conclusion of the project application review process.
The Research Peer Review Committee of the Canadian Hemophilia Society will make recommendations on the awarding of the grants and the final decision will be made by the CHS Board of Directors. No appeals will be considered.
2. Additional Grant Conditions and Grantee Obligations
2.1 Statement of Expenditures
A statement of all expenditures for the grant, signed by the candidate and the financial officer of each institution, must be received at the CHS's offices within 2 months of the end date of the grant term. An institution finance/expenditure report is acceptable to avoid duplication of effort by the researcher. Failure to fulfill this requirement may lead to exclusion from future research grant competitions. If delay is anticipated, the CHS must be informed.
2.2 Use of the Grants
The Grant is to be used mainly to support the salary of the grantee, research assistant and project expenses.
Grantees must devote full time or part time to the research during the tenure of the Grant as per their proposal which has been accepted by the CHS.
Please note that awardees must notify the Canadian Hemophilia Society immediately if there is any change to the research or its term.
The use of funds for purposes other than stated in the application must be approved in advance by the CHS.2.3 Unexpended Balances
The Canadian Hemophilia Society does not permit carrying forward into the next grant year an unexpected balance in excess of $5,000. Prior written request to the CHS is required to carry forward a balance that exceeds $5,000. 2.4 Termination of the Grant
Upon termination of the Grant, any unexpended balance of funds must be returned to the CHS. 2.5 Travel Expenses
A grantee may use $1,500 annually from the award for the purpose of travel in connection with the grant and, if needed, an additional amount representing one percent (1%) of the annual value of the award. 2.6 Title to Equipment
Title to any equipment obtained with the Canadian Hemophilia Society's funds shall be held by the host institution on the condition that for a 12 month period following termination of grant, the CHS may transfer title to another institution. Prior written authorization for the transfer of funds or equipment by a grantee to another institution must be obtained from the CHS.2.7 Interim, Final Report & Abstract Requirements
Research grant recipients are required to provide a project progress report; this report summarizing the progress to date will serve as the basis for project continuance and will also provide supporting rationale, if required, for approval of project modifications, and/or extension requests.
Within 2 months of the end of the funding period, the Canadian Hemophilia Society requires a final report on activities undertaken during the tenure of the Grant and on the results of the project. The CHS also requires that the researcher provide an approximately 250-word lay abstract (Grade 12 readability) describing his or her activities and the results of the project for inclusion in the Society's publications and for presentation at the CHS medical and scientific symposia.
Failure to fulfill these requirements can lead to exclusion from future fellowship/research grant competitions. If delay is anticipated, the CHS must be informed.2.8 Acknowledgement of Support
The Canadian Hemophilia Society MUST be informed of any publications that are based on research funded by the Canadian Hemophilia Society and all such publications, scientific communications and media releases related to the award MUST acknowledge the support of the Canadian Hemophilia Society and Novo Nordisk Canada. Researchers are encouraged to present study results, when possible, even if preliminary, at hemophilia conferences (e.g., World Federation of Hemophilia Congress, Rendez-Vous, etc.). 2.9 Proprietary Rights
The CHS must be informed of any commercial exploitation arising from the CHS-supported activity. However, the CHS does not claim proprietary rights to inventions resulting from research supported by its funds. The onus is on the grantee to seek patent protection in collaboration with the university or institute for inventions or developments arising from the CHS-supported research.2.10 Indirect / Overhead Costs
Grant funds must contribute towards the direct costs of the research program or project for which the funds were awarded. The Institution provides for indirect or overhead costs, such as the costs associated with facilities and basic utilities, the purchase and repair of office equipment, administration fees, insurance for equipment and research vehicles, and basic communication devices such as telephones and fax machines. The funds must be used effectively and economically, and the expenses must be essential for the research supported by the grant.
Health Charities Coalition of Canada Position Statement
on Indirect Costs of Research (May 14, 2007): It is the policy of the Health Charities Coalition of Canada (HCCC) that health charities should not fund the indirect costs associated with the research they fund. All HCCC members have agreed not to fund indirect costs. While the HCCC recognizes that these may indeed be legitimate expenditures, we believe the funding of such costs is the responsibility of governments and not donors.
While the CHS is not a member of HCCC, it nonetheless supports the position that indirect costs associated with research it funds and fellows it supports are the responsibility of governments and/or research institutions and not its donors.
3. Ethical Considerations
3.1 Adherence to Research Guidelines
An application to the
Canadian Hemophilia Society for research support constitutes a pledge
on the part of the applicants and their research institutions to respect
all the guidelines of the Canadian Hemophilia Society, the Tri-Council
Policy Statement: Ethical Conduct for Research Involving Humans,
December 2010 (TCPS2), the Canadian Institutes of Health Research
(CIHR), Natural Sciences and Engineering Research Council of Canada,
Social Sciences and Humanities Research Council of Canada and the
Canadian Council on Animal Care. In the event that these guidelines are
not adhered to, the CHS will withhold funding.
required for research involving human subjects, gene therapy in humans,
animals and biohazards must be received by the CHS as soon as possible;
funding of successful applications for research will be withheld by the
CHS until full Research Ethics Board approval is provided in writing to
the CHS. CHS review of the applications, by its Peer Review Committee,
can proceed prior to Research Ethics Board (REB) approval.3.2 Research Involving Human Subjects
project in a research proposal involving human subjects and gene
therapy in humans must submit the complete designated form, authorized
by the local institutional Research Ethics Board in accordance with the
TCPS2 document of the Canadian Institutes of Health Research, Natural
Sciences and Engineering Research Council of Canada,and Social Sciences
and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010
. The Tri-Council Policy Statement is available from the following website: www.pre.ethics.gc.ca/pdf/eng/tcps2/TCPS_2_FINAL_Web.pdf
responsibility for filing a Clinical Trial Application ( CTA) with
Health Canada for a human drug clinical trial rests with the Principal
Investigator. Guidance on whether a CTA is required is found at: www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clini/cta-eng.php
See: Overview of the Clinical Trial Application Process and Institution/Investigator Initiated Clinical Trials.
addition, all continuing grantees involved in human subjects must
submit the complete designated form on an annual basis. Receipt of this
form is required for continuation of payment by the CHS of any funds
committed for the following year. 3.3 Research on Somatic Cell Gene Therapy in Humans The Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010
must be adhered to. Any research related to this area must be reviewed by the local institutional Research Ethics Board.
3.4 Care and Use of Experimental Animals
CHS requires that all experiments involving animals be conducted in an
ethical way. The facilities for, and the care and use of animals, in any
investigation the CHS supports must be in strict accordance with the
guidelines set out by the Canadian Council on Animal Care (CCAC) in its
publication, Guide to the Care and Use of Experimental Animals (Vol. 1,
1980 and revised in 1993; Vol. 2, 1984), available from: The Canadian Council on Animal Care
1000 - 151 Slater St.
Ottawa, Ontario Canada K1P 5H3
proposal involving animals must have one copy of the designated form,
completed and authorized by a local institutional Animal Care Committee,
confirming its ethical acceptability (the composition of the committee
is set forth in the CCAC Guide). In addition, all continuing grantees
involved in research using animals must submit one complete form on an
annual basis. Receipt of this form is required for continuation of
payment by the CHS of any funds committed for the following year.
3.5 Research Involving Biohazards
proposing to engage in research involving animal and human pathogens
and animal cells are required to comply with the Canadian Institutes of
Health Research and Health and Welfare Canada Biosafety Laboratory
Guidelines, 3rd Edition – 2004. These guidelines were jointly prepared
with the Office of Biosafety of the Laboratory Centre for Disease
Control of Health Canada and are available from: Office of Biosafety
Laboratory Centre for Disease Control
Health Protection Branch
Ottawa, Ontario Canada K1A 0L2
or at www.phac-aspc.gc.ca/publicat/lbg-ldmbl-04/index-eng.php
These Guidelines cover the following types of research:
a) research involving animal and human pathogens;
b) research involving animal cells in culture;
c) research involving recombinant DNA molecules which might be harmful to humans, animals or the environment.
proposal involving research proposals covering the areas noted above
must have one completed form, authorized by a local institutional
committee, confirming that the level of containment implemented by the
investigator meets the Canadian Institutes of Health Research's
In addition, all continuing grantees participating
in research involving biohazards must submit a completed form on an
annual basis. Receipt of this form is required for continuation of
payment by CHS of any funds committed for the following year. Disposal of Hazardous and Radio Active Materials3.6 Research Involving Hazardous Compounds
are responsible for ensuring that their research conforms with the
provincial statutes regarding disposal of chemical wastes. Researchers
are also responsible for ensuring that research assistants and
laboratory personnel are aware of any hazards posed by materials
required for the research, that these personnel are adequately trained
in handling and containment of such compounds, and that protective
procedures are enforced, in compliance with the Occupational Health and
Safety regulations of the province in which work is carried out. 3.7 Research Involving Radioactive Materials
who will be carrying out research using radioactive materials must be
aware of, and comply with, all Atomic Energy Control Board regulations,
recommended procedures, and safety precautions governing the use of such
materials in Canada. Further information may be obtained from:Office of Public Information
Atomic Energy Control Board
P.O. Box 1046, Station 'B'
270 Albert Street
Ottawa, Ontario Canada K1P 5S9
Tel: 613-995-5894 Fax: 613-995-5086